All Stories

  1. a vaccine prevents loss of cognition.
  2. Vaccines can prevent dementia
  3. Vaccines and dementia
  4. Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer’s Disease
  5. Evaluation of BCG Vaccination and Plasma Amyloid: A Prospective, Pilot Study with Implications for Alzheimer’s Disease
  6. Adult Vaccination, Getting to Know Their Nonspecific Effects
  7. Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
  8. Poly(Vinyl Alcohol)‐Hydrogel Microparticles with Soft Barrier Shell for the Encapsulation of Micrococcus luteus
  9. Bladder Cancer Immunotherapy by BCG is associated with a significantly reduced risk of Alzheimer‘s disease
  10. Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer’s disease in bladder cancer patients
  11. Can immunization with Bacillus Calmette-Guérin (BCG) protect against Alzheimer’s disease?
  12. BCG vaccination for bovine tuberculosis; conclusions from the Jerusalem One Health workshop
  13. Biosorption of copper from aqueous environments by Micrococcus luteus in cell suspension and when encapsulated
  14. Evolutionary Genomics and Conservation of the Endangered Przewalski’s Horse
  15. Living Composites of Electrospun Yeast Cells for Bioremediation and Ethanol Production
  16. Evolutionary changes in the genome of Mycobacterium tuberculosis and the human genome from 9000 years BP until modern times
  17. Living Composites of Bacteria and Polymers as Biomimetic Films for Metal Sequestration and Bioremediation
  18. Blocked Bacteria Escape by ATRP Grafting of a PMMA Shell on PVA Microparticles
  19. Simultaneous detection of <I>Mycobacterium bovis</I> and <I>M. tuberculosis</I> in an apparently immunocompetent patient [Correspondence]
  20. Mycobacterium tuberculosis Complex Lipid Virulence Factors Preserved in the 17,000-Year-Old Skeleton of an Extinct Bison, Bison antiquus
  21. Rapid Differentiation of Mycobacterium tuberculosis and M. bovis by High-Resolution Melt Curve Analysis
  22. Pulmonary tuberculosis in the West Bank, Palestinian Authority: molecular diagnostic approach
  23. Rapid Differentiation of Mycobacterium tuberculosis and M. bovis by High-Resolution Melt Curve Analysis
  24. Molecular Exploration of the First-Century Tomb of the Shroud in Akeldama, Jerusalem
  25. Biomolecular archaeology of ancient tuberculosis: response to “Deficiencies and challenges in the study of ancient tuberculosis DNA” by Wilbur et al. (2009)
  26. Genome Sequence of the Fleming Strain of Micrococcus luteus, a Simple Free-Living Actinobacterium
  27. Structural Changes and Cellular Localization of Resuscitation-Promoting Factor in Environmental Isolates of Micrococcus luteus
  28. Detection and Molecular Characterization of 9000-Year-Old Mycobacterium tuberculosis from a Neolithic Settlement in the Eastern Mediterranean
  29. Attempts to revive Mycobacterium tuberculosis from 300-year-old human mummies
  30. Microsatellite genotyping of cultivars of the Holy Land grapevine, Vitis vinifera ssp. sativa (Vitaceae)
  31. Mode of Action of Fenarimol Against Leishmania Spp.
  32. A PCR method for detection of plant meals from the guts of insects
  33. Leishmaniasis in Ancient Egypt and Upper Nubia
  34. Short Communication: Palestinian infantile visceral leishmaniasis caused by a genetic variant of Leishmania infantum belonging to a new zymodeme
  35. Co–infection ofMycobacterium tuberculosisandMycobacterium lepraein human archaeological samples: a possible explanation for the historical decline of leprosy
  36. Genetic and biological diversity among populations of Leishmania major from Central Asia, the Middle East and Africa
  37. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA
  38. Micrococcus luteus - Survival in Amber
  39. Polymorphism among alleles of the 6-Phosphogluconate dehydrogenase gene from Leishmania major and Leishmania tropica
  40. Epidemiology of visceral leishmaniasis in the Jenin District, West Bank: 1989-1998.
  41. Genetic evidence for the origin of the agrimi goat (Capra aegagrus cretica)
  42. Mycobacterium tuberculosisComplex DNA from an Extinct Bison Dated 17,000 Years before the Present
  43. THE GENETIC SIGNATURE OF THE DEAD SEA SCROLLS
  44. Diversity of Microorganisms Isolated from Amber
  45. Determining the Sex of Infanticide Victims from the Late Roman Era through Ancient DNA Analysis
  46. DNA analysis reveals the sex of infanticide victims
  47. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine
  48. Analysis of Parchment Fragments from the Judean Desert Using DNA Techniques
  49. Sex identification of archaeological human remains based on amplification of the X and Y amelogenin alleles
  50. Cutaneous leishmaniasis: The prospects for a killed vaccine
  51. Leishmania major: glycolipid antigens recognized by immune human sera
  52. Development of Sandfly Forms of Leishmania major in Sucrose Solutions
  53. Cultivation of Besnoitia besnoiti and evaluation of susceptibility of laboratory animals to cultured parasites
  54. Leishmania major: Solid phase radioimmunoassay for antibody detection in human cutaneous leishmaniasis
  55. Parasite immunology and lymphocyte population dynamics
  56. Lipid and Lipopolysaccharide‐Like Antigens of Leishmania Promastigotes1
  57. Specific antibodies to precipitated from serum of cattle by live parasites and by soluble antigen
  58. C-Reactive Protein Binds Leishmanial Excreted Factors
  59. Interaction of aminoglycosides and ionophores in the killing ofCrithidia fasciculata
  60. Phenotypic diversity of cloned lines ofLeishmania major promastigotes
  61. Enzyme linked immunosorbent assay for detection of antibodies againstBesnoitia besnoiti in cattle
  62. Leishmania tropica: Protective response in C3H mice vaccinated with excreted factor crosslinked with the synthetic adjuvant, muramyl dipeptide
  63. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals.
  64. An amphipathic sulphated glycoconjugate of Leishmania: characterization with monoclonal antibodies.
  65. Growth inhibition ofLeishmania tropicaamastigotesin vitroby rifampicin combined with amphotericin B
  66. Leishmanial excreted factors (EF) are distinguished by characteristic electrophoretic mobilities
  67. Surface reaction ofLeishmania
  68. Monoclonal antibodies for serotyping Leishmania strains
  69. The cellular and humoral immune response in subjects vaccinated against cutaneous leishmaniasis using Leishmania tropica major promastigotes
  70. Leishmania tropica and Leishmania donovani: Solid phase radioimmunoassay using leishmanial excreted factor
  71. Action of leishmanial excreted factor (EF) on human lymphocyte blast transformation
  72. Binding ofLeishmania promastigotes to macrophages
  73. Frozen stored Leishmania tropica vaccine: the effects of dose, route of administration and storage on the evolution of the clinical lesion. Two field trials in the Israel Defense Forces
  74. Leishmanial excreted factors (EFs): Purification by affinity chromatography
  75. Therapeutic Effect of Rifampicin and Isoniazid against Leishmania tropica major
  76. Surface reaction ofLeishmania
  77. Age-related changes in rat liver total protein and transferrin synthesis
  78. Identification of galactose as the immunodominant sugar of leishmanial excreted factor and subsequent labeling with galactose oxidase and sodium boro[3H]hydride
  79. Rifampicin Treatment of Cutaneous Leishmaniasis
  80. Surface reaction ofLeishmania
  81. Cellular changes in bone marrow of malaria-infected mice
  82. Ultrastructural characteristics of cell division in
  83. DO LEISHMANIA SEROTYPES MIMIC HUMAN BLOOD GROUP ANTIGENS?
  84. Adoptive transfer of immunity toPlasmodium berghei after busulfan and cyclophosphamide treatment of recipient mice
  85. Inhibitory activity of sinefungin and siba (5′‐deoxy‐5′‐S‐isobutylthio‐adenosine) on the growth of promastigotes and amastigotes of different species of leishmania
  86. Cellular changes in the bone marrow of Plasmodium berghei-infected mice
  87. An improved protocol for the preparation of a frozen promastigote vaccine for cutaneous leishmaniasis
  88. Production and secretion of Leishmania braziliensis proteins
  89. Leishmania spp.: Cellular levels and synthesis of polyamines during growth cycles
  90. Leishmania spp.: Effect of inhibitors on growth and on polyamine and macromolecular syntheses
  91. Leishmanial Excreted Factor: Protein-Bound and Free Forms from Promastigote Cultures of Leishmania tropica and Leishmania donovani
  92. Polyamine synthesis and levels during the growth and replication of Leishmania tropica minor and Leishmania aethiopica
  93. Leishmania donovani: Physicochemical, immunological, and biological characterization of excreted factor from promastigotes
  94. Analysis by SDS-polyacrylamide gel electrophoresis of an immunologically active factor of Leishmania tropica from growth media, promastigotes, and infected macrophages
  95. Plasmodium berghei: Relationship between mitosis and erythropoiesis in spleen cells of infected rats
  96. Isolation of a carbohydrate‐rich immunologically active factor from cultures of Leishmania tropica
  97. Trypanosoma lewisi, T. acomys and T. cruzi: A method for their cultivation with mammalian tissue
  98. Promotion of leishmanial infections in non-permissive host macrophages by conditioned medium
  99. Morphology and the differentiation of leishmanias
  100. Nutritional and immunological factors in the control of infections with Trypanosoma lewisi
  101. Trypanosoma lewisi: Immunohematopoietic interrelationships of the infection in normal, hypoxic, and rebound animals
  102. Trypanosoma lewisi: Electron microscopy of the infected spleen
  103. THERAPEUTIC INTERFERENCE STUDIES: MECHANISMS OF INTERPOLYMER COMPETITION FOR DYES*
  104. Trypanosoma lewisi: Immune spleen cell transfer in rats
  105. Trypanosoma lewisi: In vitro behavior of rat spleen cells
  106. Chromatographic separation of a rat serum growth factor required by Trypanosoma lewisi
  107. Influence of structural factors in the acridines upon their therapeutic effectiveness. Quantum mechanical parameters
  108. Interactions between acridines and triphenyl methane dyes: Their possible role in therapeutic interference
  109. Mouse serum as an environment for the growth of Trypanosoma lewisi
  110. Some relationships between Chlorohydra, its symbionts and some other chlorophyllous forms
  111. Alterations in Fatty Acid Metabolism and Morphology of Leishmania enriettii Exposed to Elevated Temperature
  112. Identity of trypanosome growth factors in serum II. Active globulin components
  113. Regulation of cell membrane permeability in Trypanosoma lewisi
  114. Temperature effect on Leishmania enriettii in vitro
  115. Synthesis of α-Linolenic Acid by Leishmania enriettii
  116. Effects of temperature on morphologic variation of Schizotrypanum cruzi in tissue culture
  117. Peace-Corps Physicians
  118. Excessive Variation in Radiation-induced Chromosome Aberrations
  119. The Evaluation of X-ray-induced Chromosome Aberrations in Cell-cultures of the Chinese Hamster
  120. Absorption Microscopy of Enzymatically Treated Cell-Free Chloroplasts
  121. Effects of Some Metabolic Inhibitors on the Pigments of Euglena gracilis in an Acidic Medium
  122. A Pheophytin‐like Pigment in Dark‐Adapted Euglena gracilis
  123. Biochemical and physiological differentiation during morphogenesis. XIX. Alkaline phosphatase and aldolase activities in the developing cerebral cortex and liver of the fetal guinea pig
  124. Environmental Factors Affecting Growth and Chlorophyll Synthesis in Euglena.* I. Physical and Chemical. II. The Effectiveness of the Spectrum for Chlorophyll Synthesis.
  125. Historical Trends in the Antimalarial Campaign in Palestine And Israel